AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

New CaviWipes 2.0 Earns EPA’s Emerging Viral Pathogen Claim; Proves Effective Against 42 Pathogens Including SARS-CoV-2 and Candida Auris

April 5, 2021 GMT
CaviWipes™ 2.0 surface disinfectant wipes are effective against 42 pathogens, including SARS-CoV-2, and are fully qualified for the Environmental Protection Agency’s (EPA) Emerging Viral Pathogen Claim. (Photo: Business Wire)
CaviWipes™ 2.0 surface disinfectant wipes are effective against 42 pathogens, including SARS-CoV-2, and are fully qualified for the Environmental Protection Agency’s (EPA) Emerging Viral Pathogen Claim. (Photo: Business Wire)

ORANGE, Calif.--(BUSINESS WIRE)--Apr 5, 2021--

Metrex has released its new CaviWipes™ 2.0 surface disinfectant wipes that are effective against 42 pathogens, including SARS-CoV-2, and is fully qualified for the Environmental Protection Agency’s (EPA) Emerging Viral Pathogen Claim. 1 The multi-purpose disinfectant wipes have a two-minute universal contact time for one-step cleaning and disinfection of hard, non-porous surfaces in healthcare settings.

ADVERTISEMENT

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210405005008/en/

CaviWipes™ 2.0 surface disinfectant wipes are effective against 42 pathogens, including SARS-CoV-2, and are fully qualified for the Environmental Protection Agency’s (EPA) Emerging Viral Pathogen Claim. (Photo: Business Wire)

“During unpredictable public health crises, infection preventionists and healthcare professionals learn new behaviors and use new tools to maintain employee and patient safety,” said James Chia, Director of Research and Development at Metrex. “As front-line workers navigate today’s extremely demanding environment, access to quick-working surface disinfectants like CaviWipes 2.0 gives them confidence that they are cleaning and disinfecting against ever-evolving pathogens.”

In the last decade, EPA created a voluntary, two-stage process to enable the use of certain EPA-registered disinfectant products against emerging viral pathogens not identified on its original product label. With the approval of an emerging viral pathogen claim, EPA-registered disinfectant products can make specific claims against an outbreak virus.

EPA’s Emerging Viral Pathogen claim indicates that CaviWipes 2.0 meets current and future infection prevention needs for all virus types, including enveloped, large and small non-enveloped viruses. CaviWipes 2.0 is on the EPA’s List N as a disinfectant for use against SARS-CoV-2, the virus that causes COVID-19.

ADVERTISEMENT

Proven to kill a broad spectrum of bacteria, viruses and pathogenic fungi quickly and efficiently, CaviWipes 2.0 is effective against a total of 42 pathogens, including SARS-CoV-2, Candida auris, Norovirus, Mycobacterium tuberculosis (TB), Methicillin-Resistant Staphylococcus aureus (MRSA) and Human Immunodeficiency Virus Type 1 (HIV-1).

With a neutral pH of 7.5, the low alcohol disinfectant wipes contain a next-generation formula that uses a multi-pronged approach for attacking and destroying pathogens while remaining gentle on material surfaces.

“With a new, powerful formula, CaviWipes 2.0 maximizes the synergies among its ingredients to kill infectious pathogens found in healthcare environments,” said Chia. “Compatible across a wide variety of hard, non-porous surfaces, CaviWipes 2.0 delivers on Metrex’s 30-year-old, proven record of distributing infection prevention products that are gentle on the surfaces of medical materials and equipment.”

Metrex CaviWipes™ and CaviCide™ product lines offer a number of broad-spectrum surface disinfectant products considered effective against SARS-CoV-2 to reduce the risk of cross-contamination while compatible with most medical device surfaces. For more information, visit www.metrex.com.

About Metrex Research LLC

Metrex Research, LLC (Metrex) has worked for more than 30 years to provide value-added infection prevention products and services in global healthcare environments. Metrex offers a complete line of high-quality enzymatic detergents, high-level disinfectants/sterilants, surface disinfectants for use in hospitals, liquid medical waste disposal products, hand hygiene products, eye shields and many other infection prevention products. For more information, visit www.metrex.com.

1 CaviWipes 2.0 meets the criteria to make claims against emerging viral pathogens from the Enveloped Viruses, Large and Small Non-Enveloped Viral categories. www.epa.gov/sites/production/files/2016-09/documents/emerging_viral_pathogen_program_guidance_final_8_19_16_001_0.pdf

View source version on businesswire.com:https://www.businesswire.com/news/home/20210405005008/en/

CONTACT: Media Contacts:

Hannah Minton

Portavoce PR for Metrex

760-479-5749

Hannah.Minton@portavocepr.comDenise Montenegro

Metrex

714-817-5430

Denise.Montenegro@metrex.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: MEDICAL SUPPLIES RETAIL HEALTH INFECTIOUS DISEASES HOME GOODS SPECIALTY

SOURCE: Metrex

Copyright Business Wire 2021.

PUB: 04/05/2021 11:00 AM/DISC: 04/05/2021 11:01 AM

http://www.businesswire.com/news/home/20210405005008/en